Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Celldex Therapeutics (CLDX)

September 26, 2024 6:28 AM EDT Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $80.00 price target on Celldex Therapeutics (NASDAQ: CLDX).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login